DE602004009301T2 - Chimäre polypeptide und ihre verwendung - Google Patents

Chimäre polypeptide und ihre verwendung Download PDF

Info

Publication number
DE602004009301T2
DE602004009301T2 DE602004009301T DE602004009301T DE602004009301T2 DE 602004009301 T2 DE602004009301 T2 DE 602004009301T2 DE 602004009301 T DE602004009301 T DE 602004009301T DE 602004009301 T DE602004009301 T DE 602004009301T DE 602004009301 T2 DE602004009301 T2 DE 602004009301T2
Authority
DE
Germany
Prior art keywords
cells
dna
cell
polypeptide
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004009301T
Other languages
German (de)
English (en)
Other versions
DE602004009301D1 (de
Inventor
Christian KÜHNE
Andras Simoncsits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adriacell SpA Trieste It
Original Assignee
ICGEB
International Centre for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICGEB, International Centre for Genetic Engineering and Biotechnology filed Critical ICGEB
Publication of DE602004009301D1 publication Critical patent/DE602004009301D1/de
Application granted granted Critical
Publication of DE602004009301T2 publication Critical patent/DE602004009301T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE602004009301T 2003-04-18 2004-04-16 Chimäre polypeptide und ihre verwendung Expired - Lifetime DE602004009301T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.
ITMI20030821 2003-04-18
PCT/EP2004/004062 WO2004092194A2 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use

Publications (2)

Publication Number Publication Date
DE602004009301D1 DE602004009301D1 (de) 2007-11-15
DE602004009301T2 true DE602004009301T2 (de) 2008-07-17

Family

ID=33187374

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004009301T Expired - Lifetime DE602004009301T2 (de) 2003-04-18 2004-04-16 Chimäre polypeptide und ihre verwendung

Country Status (16)

Country Link
US (3) US20060292629A1 (https=)
EP (1) EP1616011B1 (https=)
JP (2) JP4794432B2 (https=)
KR (2) KR101360781B1 (https=)
CN (1) CN100584950C (https=)
AT (1) ATE374826T1 (https=)
AU (1) AU2004230254B2 (https=)
CA (1) CA2522525A1 (https=)
CY (1) CY1107115T1 (https=)
DE (1) DE602004009301T2 (https=)
DK (1) DK1616011T3 (https=)
ES (1) ES2293247T3 (https=)
IT (1) ITMI20030821A1 (https=)
PL (1) PL1616011T3 (https=)
PT (1) PT1616011E (https=)
WO (1) WO2004092194A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
MX2007010073A (es) * 2005-02-18 2007-10-10 Astrazeneca Ab Metodo para determinar la respuesta de los inhibidores de chk1.
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
WO2008141096A2 (en) * 2007-05-11 2008-11-20 The Regents Of The University Of California Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them
HK1231556A1 (zh) 2014-02-17 2017-12-22 克劳德贝尔纳里昂第一大学 确定组织放射敏感性的预测方法
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
WO2017178885A2 (en) * 2016-04-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency
JP6925003B2 (ja) * 2016-05-10 2021-08-25 公立大学法人横浜市立大学 非相同末端連結欠損細胞及びその利用
AU2017271678B2 (en) * 2016-05-27 2021-05-06 Synthex, Inc. Protein interfaces
EP3469070B1 (en) * 2016-06-09 2021-08-04 Alma Mater Studiorum - Università di Bologna Herpesvirus with modified glycoprotein b
WO2018232356A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
JP7101419B2 (ja) 2017-10-27 2022-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 内因性ｔ細胞受容体の標的置換
GB2584210B (en) 2017-11-22 2022-03-16 Synthex Inc Peptides for inhibiting RAD51
JP2024537991A (ja) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
WO2023111213A1 (en) 2021-12-16 2023-06-22 Rdp Pharma Ag Cell penetrating polypeptides (cpps) and their use in human therapy
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途
EP4480497A1 (en) 2023-06-21 2024-12-25 RDP Pharma AG Bio-conjugates for oncology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
CA2361191A1 (en) * 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
EP1165819A2 (en) * 1999-03-31 2002-01-02 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
EP2806025B1 (en) * 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.

Also Published As

Publication number Publication date
JP2011182792A (ja) 2011-09-22
WO2004092194A2 (en) 2004-10-28
CY1107115T1 (el) 2012-01-25
DE602004009301D1 (de) 2007-11-15
JP4794432B2 (ja) 2011-10-19
CA2522525A1 (en) 2004-10-28
KR20060003029A (ko) 2006-01-09
CN1768142A (zh) 2006-05-03
CN100584950C (zh) 2010-01-27
PL1616011T3 (pl) 2008-05-30
PT1616011E (pt) 2008-01-07
US20150018409A1 (en) 2015-01-15
KR20110074948A (ko) 2011-07-04
KR101360781B1 (ko) 2014-04-24
EP1616011A2 (en) 2006-01-18
AU2004230254A1 (en) 2004-10-28
DK1616011T3 (da) 2008-02-04
US20060292629A1 (en) 2006-12-28
EP1616011B1 (en) 2007-10-03
ITMI20030821A1 (it) 2004-10-19
WO2004092194A3 (en) 2005-03-17
JP2006523448A (ja) 2006-10-19
AU2004230254B2 (en) 2008-10-02
US20110033384A1 (en) 2011-02-10
ATE374826T1 (de) 2007-10-15
ES2293247T3 (es) 2008-03-16
KR101247704B1 (ko) 2013-03-26

Similar Documents

Publication Publication Date Title
DE602004009301T2 (de) Chimäre polypeptide und ihre verwendung
DE60123133T2 (de) Positionsabhängige erkennung des gnn nucleotidtripletts durch zinkfinger
Siaud et al. Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains
Moynahan et al. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
DE69838748T2 (de) Feststellung molekularer interaktionen durch marker-untereinheiten-komplementation
Jackson et al. Analysis of the human replication protein A: Rad52 complex: evidence for crosstalk between RPA32, RPA70, Rad52 and DNA
DE3587465T2 (de) Vielfache Drogen-Resistenz in Säugetierzellinien und Isolierung der determinanten Glykoprotein-DNS.
KR102683424B1 (ko) 타우 응집과 관련된 유전적 취약성을 식별하기 위한 CRISPR/Cas 드랍아웃 스크리닝 플랫폼
CN118109438A (zh) 工程化的CRISPR/Cas13系统及其用途
WO2021094462A1 (de) Adaptersystem artifizieller nichtribosomaler peptidsynthetasen und polyketidsynthasen
Van de Ven Genetic basis of uterine leiomyoma: involvement of high mobility group protein genes
DE69411934T2 (de) Ein detektionssystem für mutagene, dass mutagenische änderungen auch identifiziert
Roy et al. DNA-binding properties of Smc6, a core component of the Smc5–6 DNA repair complex
DE69628936T2 (de) Test zur identifikation von inhibitoren der interaktion zwischen p53 und dm2 proteinen
DE69813193T2 (de) Verfahren und mittel bezogen auf retrotransposon und retrovirale integration
DE60115039T2 (de) Screeningverfahren für modulatoren von methyltransferase abhängiger chromosomenstabilität
Münick Designed Ankyrin Repeat Proteins targeting the p53 family: a novel approach for cancer therapy
Tam et al. Location-specific functions of the two forkhead-associated domains in Rad53 checkpoint kinase signaling
Sugasawa DNA Damage Recognition for Mammalian Global Genome Nucleotide Excision Repair
Etchin Roles of BRCA2 and PALB2 in homology-directed repair of chromosomal breaks
Finnegan Mechanisms of G2 chromosomal radiosensitivity of murine SCID cells
Friedberg et al. The 2nd US–Japan DNA Repair Meeting, Honolulu, Hawaii, June 4–8, 2004
EP0919631A1 (de) Verfahren zum Identifizieren einer Nukleinsäure
Wang Characterizing the Regulation of Mitochondrial Nucleoids
Lesterlin A dual role for the FtsK protein in Escherichia coli chromosome segregation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ADRIACELL S.P.A., TRIESTE, IT